Github Auto Build at 2023-11-02 19:58

npnpatidar · Nov 2, 2023 · 194ca54 · 194ca54
1 parent d16868a
commit 194ca54
Show file tree

Hide file tree

Showing 8 changed files with 34 additions and 4 deletions.
diff --git a/feeds/Explain_FP.xml b/feeds/Explain_FP.xml
diff --git a/feeds/Explained_IE.xml b/feeds/Explained_IE.xml
@@ -180,4 +180,4 @@ A trial run of goods trains was successful, and discussions between the governme
 
 The project faced delays due to land acquisition issues and the COVID-19 pandemic. However, it holds great practical and emotional significance for Tripura, as the state shares an 856-km international border with Bangladesh and played a significant role in sheltering refugees during the Indo-Pakistan war and the creation of Bangladesh.
 
-This rail link is part of ongoing efforts to strengthen connectivity between India and Bangladesh. The Bandhan Express, Maitree Express, and Mitali Express are already running between West Bengal and Bangladesh. The Bandhan Express reconnects Kolkata and Khulna, the third-largest city in Bangladesh. The Maitree Express has been operating between Kolkata and Dhaka Cantonment since 2008, and the Mitali Express was announced during Prime Minister Modi's visit to Dhaka in 2021, connecting Siliguri with the Bangladesh capital.</description><pubDate>Thu, 02 Nov 2023 01:37:57 +0000</pubDate></item><item><title>India’s own CAR-T cell therapy: What is it, when will it be available, and at what cost?</title><link>https://indianexpress.com/article/explained/indias-own-car-t-cell-therapy-what-is-it-when-will-it-be-available-and-at-what-cost-9009776/</link><description>The Central Drugs Standard Control Organisation (CDSCO) has granted market authorization for Nexcar19, India's first indigenous CAR-T cell therapy, developed by ImmunoAct. This approval allows for the commercial launch of the therapy in India at a much lower cost compared to other countries. CAR-T therapy is a groundbreaking treatment that modifies T-cells into cancer-fighting cells. Unlike chemotherapy and immunotherapy, CAR-T therapy aims to cure cancer and provide lifelong benefits. Nexcar19 specifically targets cancer cells carrying the CD19 protein, and it has shown promising results in patients with B-cell lymphomas who did not respond to standard treatments. The therapy involves a patient's blood being genetically modified in the lab before being reintroduced into the body. Early results have shown a 70% response rate, with approximately 50% of patients achieving a complete response. Clinical trials for pediatric patients are currently underway, and the therapy has received approval for patients aged 15 years and older. Nexcar19 has demonstrated lower toxicity levels and minimal cytokine release syndrome compared to other CAR-T therapies. ImmunoAct is in the process of obtaining licenses and partnerships with hospitals to make the therapy available to more patients. The cost of treatment is currently around Rs 30-40 lakh, but efforts are being made to reduce it to Rs 10-20 lakh in the future. Discussions will also be held with insurers and the government to clarify the extent of insurance coverage for the therapy.</description><pubDate>Thu, 02 Nov 2023 01:37:51 +0000</pubDate></item></channel></rss>
+This rail link is part of ongoing efforts to strengthen connectivity between India and Bangladesh. The Bandhan Express, Maitree Express, and Mitali Express are already running between West Bengal and Bangladesh. The Bandhan Express reconnects Kolkata and Khulna, the third-largest city in Bangladesh. The Maitree Express has been operating between Kolkata and Dhaka Cantonment since 2008, and the Mitali Express was announced during Prime Minister Modi's visit to Dhaka in 2021, connecting Siliguri with the Bangladesh capital.</description><pubDate>Thu, 02 Nov 2023 01:37:57 +0000</pubDate></item><item><title>India’s own CAR-T cell therapy: What is it, when will it be available, and at what cost?</title><link>https://indianexpress.com/article/explained/indias-own-car-t-cell-therapy-what-is-it-when-will-it-be-available-and-at-what-cost-9009776/</link><description>The Central Drugs Standard Control Organisation (CDSCO) has granted market authorization for Nexcar19, India's first indigenous CAR-T cell therapy, developed by ImmunoAct. This approval allows for the commercial launch of the therapy in India at a much lower cost compared to other countries. CAR-T therapy is a groundbreaking treatment that modifies T-cells into cancer-fighting cells. Unlike chemotherapy and immunotherapy, CAR-T therapy aims to cure cancer and provide lifelong benefits. Nexcar19 specifically targets cancer cells carrying the CD19 protein, and it has shown promising results in patients with B-cell lymphomas who did not respond to standard treatments. The therapy involves a patient's blood being genetically modified in the lab before being reintroduced into the body. Early results have shown a 70% response rate, with approximately 50% of patients achieving a complete response. Clinical trials for pediatric patients are currently underway, and the therapy has received approval for patients aged 15 years and older. Nexcar19 has demonstrated lower toxicity levels and minimal cytokine release syndrome compared to other CAR-T therapies. ImmunoAct is in the process of obtaining licenses and partnerships with hospitals to make the therapy available to more patients. The cost of treatment is currently around Rs 30-40 lakh, but efforts are being made to reduce it to Rs 10-20 lakh in the future. Discussions will also be held with insurers and the government to clarify the extent of insurance coverage for the therapy.</description><pubDate>Thu, 02 Nov 2023 01:37:51 +0000</pubDate></item><item><title>UNESCO names Kozhikode ‘city of literature’: What this tag means</title><link>https://indianexpress.com/article/explained/explained-culture/unesco-kozhikode-city-of-literature-what-this-means-9010805/</link><description>The city of Kozhikode in Kerala and Gwalior from Madhya Pradesh have been added to UNESCO's Creative Cities Network (UCCN) along with 55 other cities. These cities represent various creative fields such as literature and music. The UCCN was established in 2004 to promote cooperation among cities that prioritize creativity for sustainable urban development and currently includes 350 cities worldwide. It aims to leverage the potential of cultural industries and enhance cultural diversity while addressing challenges like climate change and inequality. Other Indian cities like Varanasi, Srinagar, and Chennai are also part of the network. Kozhikode, known for its literary tradition, has produced renowned writers and cultural figures, and Gwalior has contributed to the field of music. The UCCN enables member cities to recognize creativity as a crucial aspect of urban development and encourages partnerships between sectors to foster innovation and opportunities in the cultural sector. The network organizes an annual conference for mayors and stakeholders to exchange information and promote collaboration. Member cities are required to submit reports every four years to demonstrate their commitment to the UCCN's mission.</description><pubDate>Thu, 02 Nov 2023 12:09:10 +0000</pubDate></item><item><title>7 takeaways from GoI’s report on road accidents</title><link>https://indianexpress.com/article/explained/7-takeaways-from-goi-report-on-road-accidents-9010439/</link><description>The Ministry of Road Transport and Highways has released their annual report on road accidents in India for the year 2022. The report reveals that there were a total of 4,61,312 road accidents during the year, resulting in 1,68,491 deaths and 4,43,366 injuries. These numbers represent an increase of 11.9% in accidents, 9.4% in fatalities, and 15.3% in injuries compared to the previous year. The report highlights that over speeding was the leading cause of accidents, accounting for 72.3% of total accidents, 71.2% of deaths, and 72.8% of injuries. Driving on the wrong side was the second highest cause of accidents, accounting for 4.9% of all accidents. The data also shows that most accidents occurred on straight roads, with 67% of all accidents happening on such roads. 'Hit from back' collisions were the most common type of collision, accounting for over 21% of all collisions. The report also reveals that the majority of accidents and fatalities occurred under sunny/clear weather conditions. Two-wheelers were involved in the highest number of accidents, followed by cars and pedestrians. The report also includes information on the fatality rate, with Sikkim reporting the highest fatality rate and Ladakh and Daman &amp; Diu reporting the lowest. Tamil Nadu and Madhya Pradesh were the states with the highest number of accidents. It is important to note that the reported numbers may be lower than the actual figures.</description><pubDate>Thu, 02 Nov 2023 08:48:13 +0000</pubDate></item></channel></rss>
diff --git a/feeds/Opinion_FP.xml b/feeds/Opinion_FP.xml
Original file line number	Diff line number	Diff line change
Expand Up		@@ -180,4 +180,4 @@ A trial run of goods trains was successful, and discussions between the governme

		The project faced delays due to land acquisition issues and the COVID-19 pandemic. However, it holds great practical and emotional significance for Tripura, as the state shares an 856-km international border with Bangladesh and played a significant role in sheltering refugees during the Indo-Pakistan war and the creation of Bangladesh.

		This rail link is part of ongoing efforts to strengthen connectivity between India and Bangladesh. The Bandhan Express, Maitree Express, and Mitali Express are already running between West Bengal and Bangladesh. The Bandhan Express reconnects Kolkata and Khulna, the third-largest city in Bangladesh. The Maitree Express has been operating between Kolkata and Dhaka Cantonment since 2008, and the Mitali Express was announced during Prime Minister Modi's visit to Dhaka in 2021, connecting Siliguri with the Bangladesh capital.</description><pubDate>Thu, 02 Nov 2023 01:37:57 +0000</pubDate></item><item><title>India’s own CAR-T cell therapy: What is it, when will it be available, and at what cost?</title><link>https://indianexpress.com/article/explained/indias-own-car-t-cell-therapy-what-is-it-when-will-it-be-available-and-at-what-cost-9009776/</link><description>The Central Drugs Standard Control Organisation (CDSCO) has granted market authorization for Nexcar19, India's first indigenous CAR-T cell therapy, developed by ImmunoAct. This approval allows for the commercial launch of the therapy in India at a much lower cost compared to other countries. CAR-T therapy is a groundbreaking treatment that modifies T-cells into cancer-fighting cells. Unlike chemotherapy and immunotherapy, CAR-T therapy aims to cure cancer and provide lifelong benefits. Nexcar19 specifically targets cancer cells carrying the CD19 protein, and it has shown promising results in patients with B-cell lymphomas who did not respond to standard treatments. The therapy involves a patient's blood being genetically modified in the lab before being reintroduced into the body. Early results have shown a 70% response rate, with approximately 50% of patients achieving a complete response. Clinical trials for pediatric patients are currently underway, and the therapy has received approval for patients aged 15 years and older. Nexcar19 has demonstrated lower toxicity levels and minimal cytokine release syndrome compared to other CAR-T therapies. ImmunoAct is in the process of obtaining licenses and partnerships with hospitals to make the therapy available to more patients. The cost of treatment is currently around Rs 30-40 lakh, but efforts are being made to reduce it to Rs 10-20 lakh in the future. Discussions will also be held with insurers and the government to clarify the extent of insurance coverage for the therapy.</description><pubDate>Thu, 02 Nov 2023 01:37:51 +0000</pubDate></item></channel></rss>
		This rail link is part of ongoing efforts to strengthen connectivity between India and Bangladesh. The Bandhan Express, Maitree Express, and Mitali Express are already running between West Bengal and Bangladesh. The Bandhan Express reconnects Kolkata and Khulna, the third-largest city in Bangladesh. The Maitree Express has been operating between Kolkata and Dhaka Cantonment since 2008, and the Mitali Express was announced during Prime Minister Modi's visit to Dhaka in 2021, connecting Siliguri with the Bangladesh capital.</description><pubDate>Thu, 02 Nov 2023 01:37:57 +0000</pubDate></item><item><title>India’s own CAR-T cell therapy: What is it, when will it be available, and at what cost?</title><link>https://indianexpress.com/article/explained/indias-own-car-t-cell-therapy-what-is-it-when-will-it-be-available-and-at-what-cost-9009776/</link><description>The Central Drugs Standard Control Organisation (CDSCO) has granted market authorization for Nexcar19, India's first indigenous CAR-T cell therapy, developed by ImmunoAct. This approval allows for the commercial launch of the therapy in India at a much lower cost compared to other countries. CAR-T therapy is a groundbreaking treatment that modifies T-cells into cancer-fighting cells. Unlike chemotherapy and immunotherapy, CAR-T therapy aims to cure cancer and provide lifelong benefits. Nexcar19 specifically targets cancer cells carrying the CD19 protein, and it has shown promising results in patients with B-cell lymphomas who did not respond to standard treatments. The therapy involves a patient's blood being genetically modified in the lab before being reintroduced into the body. Early results have shown a 70% response rate, with approximately 50% of patients achieving a complete response. Clinical trials for pediatric patients are currently underway, and the therapy has received approval for patients aged 15 years and older. Nexcar19 has demonstrated lower toxicity levels and minimal cytokine release syndrome compared to other CAR-T therapies. ImmunoAct is in the process of obtaining licenses and partnerships with hospitals to make the therapy available to more patients. The cost of treatment is currently around Rs 30-40 lakh, but efforts are being made to reduce it to Rs 10-20 lakh in the future. Discussions will also be held with insurers and the government to clarify the extent of insurance coverage for the therapy.</description><pubDate>Thu, 02 Nov 2023 01:37:51 +0000</pubDate></item><item><title>UNESCO names Kozhikode ‘city of literature’: What this tag means</title><link>https://indianexpress.com/article/explained/explained-culture/unesco-kozhikode-city-of-literature-what-this-means-9010805/</link><description>The city of Kozhikode in Kerala and Gwalior from Madhya Pradesh have been added to UNESCO's Creative Cities Network (UCCN) along with 55 other cities. These cities represent various creative fields such as literature and music. The UCCN was established in 2004 to promote cooperation among cities that prioritize creativity for sustainable urban development and currently includes 350 cities worldwide. It aims to leverage the potential of cultural industries and enhance cultural diversity while addressing challenges like climate change and inequality. Other Indian cities like Varanasi, Srinagar, and Chennai are also part of the network. Kozhikode, known for its literary tradition, has produced renowned writers and cultural figures, and Gwalior has contributed to the field of music. The UCCN enables member cities to recognize creativity as a crucial aspect of urban development and encourages partnerships between sectors to foster innovation and opportunities in the cultural sector. The network organizes an annual conference for mayors and stakeholders to exchange information and promote collaboration. Member cities are required to submit reports every four years to demonstrate their commitment to the UCCN's mission.</description><pubDate>Thu, 02 Nov 2023 12:09:10 +0000</pubDate></item><item><title>7 takeaways from GoI’s report on road accidents</title><link>https://indianexpress.com/article/explained/7-takeaways-from-goi-report-on-road-accidents-9010439/</link><description>The Ministry of Road Transport and Highways has released their annual report on road accidents in India for the year 2022. The report reveals that there were a total of 4,61,312 road accidents during the year, resulting in 1,68,491 deaths and 4,43,366 injuries. These numbers represent an increase of 11.9% in accidents, 9.4% in fatalities, and 15.3% in injuries compared to the previous year. The report highlights that over speeding was the leading cause of accidents, accounting for 72.3% of total accidents, 71.2% of deaths, and 72.8% of injuries. Driving on the wrong side was the second highest cause of accidents, accounting for 4.9% of all accidents. The data also shows that most accidents occurred on straight roads, with 67% of all accidents happening on such roads. 'Hit from back' collisions were the most common type of collision, accounting for over 21% of all collisions. The report also reveals that the majority of accidents and fatalities occurred under sunny/clear weather conditions. Two-wheelers were involved in the highest number of accidents, followed by cars and pedestrians. The report also includes information on the fatality rate, with Sikkim reporting the highest fatality rate and Ladakh and Daman & Diu reporting the lowest. Tamil Nadu and Madhya Pradesh were the states with the highest number of accidents. It is important to note that the reported numbers may be lower than the actual figures.</description><pubDate>Thu, 02 Nov 2023 08:48:13 +0000</pubDate></item></channel></rss>